Status:

TERMINATED

IAEA-HypoX. Accelerated Radiotherapy With or Without Nimorazole in Squamous Cell Carcinoma of the Head and Neck

Lead Sponsor:

Danish Head and Neck Cancer Group

Collaborating Sponsors:

International Atomic Energy Agency

Danish Center for Interventional Research in Radiation Oncology (CIRRO)

Conditions:

Head and Neck Carcinoma

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

The purpose of this study is to test the hypothesis that radiotherapy of head and neck carcinoma can be improved by hypoxic modification of radiotherapy using nimorazole as a hypoxic radiosensitizer i...

Detailed Description

Squamous cell carcinoma in the head \& neck region (HNSCC) accounts for approximately 7% of all cancers worldwide \& around 75% of all HNSCC cases are seen in the less developed countries. Significan...

Eligibility Criteria

Inclusion

  • Tumor classified as stage I-IV located in oropharynx, hypopharynx, larynx (not glottic stage I-II), or oral cavity according to the TNM classification.
  • Histopathological diagnosis of invasive squamous cell carcinoma in the primary tumor.
  • Informed consent according to the Helsinki declaration and local regula-tions.
  • The patient must be candidate for external beam radical radiotherapy, and must be expected to accomplish the treatment.
  • Performance status 0-2 according to WHO criteria.
  • The patient should not have symptoms of peripheral neuropathy assessed by clinical examination.
  • Normal function of liver and kidney by routine laboratory examinations. The patient must not be pregnant

Exclusion

  • Distant metastases.
  • The patient should not be in a state or condition that could be expected to influence the outcome of treatment, or complicate the assessment or the treatment follow-up, or (apart from the present disease) reduce the life expectancy.
  • Surgical excision (except biopsy), prior or planned (including elective neck dissection).
  • The existence of synchronous multiple malignancies (not leukoplakia).

Key Trial Info

Start Date :

March 1 2012

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

May 1 2016

Estimated Enrollment :

104 Patients enrolled

Trial Details

Trial ID

NCT01507467

Start Date

March 1 2012

End Date

May 1 2016

Last Update

November 25 2016

Active Locations (6)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (6 locations)

1

Radiation Oncology Department, National Cancer Institute

Cairo, Egypt

2

Radiation Oncology Center

Tallinn, Estonia, 13419

3

Nuclear Medicine, Oncology & Radiotherapy Institute, Radiation Oncology Department G-8/3

Islamabad, Pakistan

4

Karachi Institute of Radiotherapy and Nuclear Medicine

Karachi, Pakistan